Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI

Van Arsdale A, Miller DT, Kuo DY, Isani S, Sanchez L and Nevadunsky NS: Association of obesity with survival in patients with endometrial cancer. Gynecol Oncol. 154:156–162. 2019. View Article : Google Scholar : PubMed/NCBI

Yang X and Wang J: The Role of Metabolic Syndrome in Endometrial Cancer: A Review. Front Oncol. 9:7442019. View Article : Google Scholar : PubMed/NCBI

Lynch HT, Snyder CL, Shaw TG, Heinen CD and Hitchins MP: Milestones of Lynch syndrome: 1895–2015. Nat Rev Cancer. 15:181–194. 2015. View Article : Google Scholar : PubMed/NCBI

Boretto M, Maenhoudt N, Luo X, Hennes A, Boeckx B, Bui B, Heremans R, Perneel L, Kobayashi H, Van Zundert I, et al: Patient-derived organoids from endometrial disease capture clinical heterogeneity and are amenable to drug screening. Nat Cell Biol. 21:1041–1051. 2019. View Article : Google Scholar : PubMed/NCBI

Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI

Morice P, Leary A, Creutzberg C, Abu-Rustum N and Darai E: Endometrial cancer. Lancet. 387:1094–1108. 2016. View Article : Google Scholar : PubMed/NCBI

Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, Tatebe K and Veneris JL: Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 69:258–279. 2019.PubMed/NCBI

Han G, Sidhu D, Duggan MA, Arseneau J, Cesari M, Clement PB, Ewanowich CA, Kalloger SE and Köbel M: Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol. 26:1594–1604. 2013. View Article : Google Scholar : PubMed/NCBI

Zannoni GF, Vellone VG, Arena V, Prisco MG, Scambia G, Carbone A and Gallo D: Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? A clinical-pathological and immunohistochemical study. Virchows Arch. 457:27–34. 2010. View Article : Google Scholar : PubMed/NCBI

Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al Cancer Genome Atlas Research Network, : Integrated genomic characterization of endometrial carcinoma. Nature. 497:67–73. 2013. View Article : Google Scholar : PubMed/NCBI

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, et al: Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 123:802–813. 2017. View Article : Google Scholar : PubMed/NCBI

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, et al: A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer. 113:299–310. 2015. View Article : Google Scholar : PubMed/NCBI

Kommoss S, McConechy MK, Kommoss F, Leung S, Bunz A, Magrill J, Britton H, Kommoss F, Grevenkamp F, Karnezis A, et al: Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. Ann Oncol. 29:1180–1188. 2018. View Article : Google Scholar : PubMed/NCBI

Kim M, Suh DH, Lee KH, Eom KY, Toftdahl NG, Mirza MR and Kim JW: Major clinical research advances in gynecologic cancer in 2018. J Gynecol Oncol. 30:e182019. View Article : Google Scholar : PubMed/NCBI

Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL and Haanen J: Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 15:457–472. 2015. View Article : Google Scholar : PubMed/NCBI

Dracopoli NC and Boguski MS: The evolution of oncology companion diagnostics from signal transduction to immuno-oncology. Trends Pharmacol Sci. 38:41–54. 2017. View Article : Google Scholar : PubMed/NCBI

Kowanetz M, Zou W, Gettinger SN, Koeppen H, Kockx M, Schmid P, Kadel EE III, Wistuba I, Chaft J, Rizvi NA, et al: Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). Proc Natl Acad Sci USA. 115:E10119–E10126. 2018. View Article : Google Scholar : PubMed/NCBI

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, et al: Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 379:722–730. 2018. View Article : Google Scholar : PubMed/NCBI

Vanderstraeten A, Tuyaerts S and Amant F: The immune system in the normal endometrium and implications for endometrial cancer development. J Reprod Immunol. 109:7–16. 2015. View Article : Google Scholar : PubMed/NCBI

Deligdisch L: Morphologic correlates of host response in endometrial carcinoma. Am J Reprod Immunol. 2:54–57. 1982. View Article : Google Scholar : PubMed/NCBI

Silverberg SG, Sasano N and Yajima A: Endometrial carcinoma in Miyagi Prefecture, Japan: Histopathologic analysis of a cancer registry-based series and comparison with cases in American women. Cancer. 49:1504–1510. 1982. View Article : Google Scholar : PubMed/NCBI

Wira CR, Fahey JV, Ghosh M, Patel MV, Hickey DK and Ochiel DO: Sex hormone regulation of innate immunity in the female reproductive tract: The role of epithelial cells in balancing reproductive potential with protection against sexually transmitted pathogens. Am J Reprod Immunol. 63:544–565. 2010. View Article : Google Scholar : PubMed/NCBI

Pascual-García M, Bértolo C, Nieto JC, Serrat N, Espinosa Í, D'Angelo E, Muñoz R, Rovira R, Vidal S and Prat J: CD8 down-regulation on cytotoxic T lymphocytes of patients with endometrioid endometrial carcinomas. Hum Pathol. 56:180–188. 2016. View Article : Google Scholar : PubMed/NCBI

Kondratiev S, Sabo E, Yakirevich E, Lavie O and Resnick MB: Intratumoral CD8⁺ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res. 10:4450–4456. 2004. View Article : Google Scholar : PubMed/NCBI

Chang WC, Li CH, Huang SC, Chang DY, Chou LY and Sheu BC: Clinical significance of regulatory T cells and CD8⁺ effector populations in patients with human endometrial carcinoma. Cancer. 116:5777–5788. 2010. View Article : Google Scholar : PubMed/NCBI

Yamagami W, Susumu N, Tanaka H, Hirasawa A, Banno K, Suzuki N, Tsuda H, Tsukazaki K and Aoki D: Immunofluorescence-detected infiltration of CD4⁺FOXP3⁺ regulatory T cells is relevant to the prognosis of patients with endometrial cancer. Int J Gynecol Cancer. 21:1628–1634. 2011. View Article : Google Scholar : PubMed/NCBI

Sica A and Mantovani A: Macrophage plasticity and polarization: In vivo veritas. J Clin Invest. 122:787–795. 2012. View Article : Google Scholar : PubMed/NCBI

Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, et al: Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Immunity. 40:274–288. 2014. View Article : Google Scholar : PubMed/NCBI

Zeng Q and Jewell CM: Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy. Curr Opin Biotechnol. 60:138–145. 2019. View Article : Google Scholar : PubMed/NCBI

Dun EC, Hanley K, Wieser F, Bohman S, Yu J and Taylor RN: Infiltration of tumor-associated macrophages is increased in the epithelial and stromal compartments of endometrial carcinomas. Int J Gynecol Pathol. 32:576–584. 2013. View Article : Google Scholar : PubMed/NCBI

Soeda S, Nakamura N, Ozeki T, Nishiyama H, Hojo H, Yamada H, Abe M and Sato A: Tumor-associated macrophages correlate with vascular space invasion and myometrial invasion in endometrial carcinoma. Gynecol Oncol. 109:122–128. 2008. View Article : Google Scholar : PubMed/NCBI

Weber SK, Sauerwald A, Pölcher M, Braun M, Debald M, Serce NB, Kuhn W, Brunagel-Walgenbach G and Rudlowski C: Detection of lymphovascular invasion by D2-40 (podoplanin) immunoexpression in endometrial cancer. Int J Gynecol Cancer. 22:1442–1448. 2012. View Article : Google Scholar : PubMed/NCBI

Kübler K, Ayub TH, Weber SK, Zivanovic O, Abramian A, Keyver-Paik MD, Mallmann MR, Kaiser C, Serçe NB, Kuhn W, et al: Prognostic significance of tumor-associated macrophages in endometrial adenocarcinoma. Gynecol Oncol. 135:176–183. 2014. View Article : Google Scholar : PubMed/NCBI

Garzetti GG, Ciavattini A, Muzzioli M, Goteri G, Fabris N, Valensise H and Romanini C: The relationship of clinical-pathologic status and adjuvant treatment with natural killer cell activity in stage I and II endometrial carcinoma. Acta Obstet Gynecol Scand. 73:652–657. 1994. View Article : Google Scholar : PubMed/NCBI

Garzetti GG, Ciavattini A, Goteri G, Tranquilli AL, Muzzioli M, Fabris N, De Nictolis M and Romanini C: Natural killer cell activity in stage I endometrial carcinoma: Correlation with nuclear grading, myometrial invasion, and immunoreactivity of proliferating cell nuclear antigen. Gynecol Oncol. 55:111–114. 1994. View Article : Google Scholar : PubMed/NCBI

Versluis MA, Marchal S, Plat A, de Bock GH, van Hall T, de Bruyn M, Hollema H and Nijman HW: The prognostic benefit of tumour-infiltrating Natural Killer cells in endometrial cancer is dependent on concurrent overexpression of Human Leucocyte Antigen-E in the tumour microenvironment. Eur J Cancer. 86:285–295. 2017. View Article : Google Scholar : PubMed/NCBI

Chen C, Zhu YB, Qu QX, Ge Y, Huang JA, Wang Y and Zhang XG: CD40-activated apoptotic tumor cell-pulsed dendritic cell could potentially elicit antitumor immune response: Involvement of up-regulation of B7-H3 expression. J Immunother. 32:29–35. 2009. View Article : Google Scholar : PubMed/NCBI

Lijun Z, Xin Z, Danhua S, Xiaoping L, Jianliu W, Huilan W and Lihui W: Tumor-infiltrating dendritic cells may be used as clinicopathologic prognostic factors in endometrial carcinoma. Int J Gynecol Cancer. 22:836–841. 2012. View Article : Google Scholar : PubMed/NCBI

Jia J, Wang Z, Li X, Wang Z and Wang X: Morphological characteristics and co-stimulatory molecule (CD80, CD86, CD40) expression in tumor infiltrating dendritic cells in human endometrioid adenocarcinoma. Eur J Obstet Gynecol Reprod Biol. 160:223–227. 2012. View Article : Google Scholar : PubMed/NCBI

Zinovkin D and Pranjol MZ: Tumor-infiltrated lymphocytes, macrophages, and dendritic cells in endometrioid adenocarcinoma of corpus uteri as potential prognostic factors: An immunohistochemical study. Int J Gynecol Cancer. 26:1207–1212. 2016. View Article : Google Scholar : PubMed/NCBI

Inoue T, Adachi K, Kawana K, Taguchi A, Nagamatsu T, Fujimoto A, Tomio K, Yamashita A, Eguchi S, Nishida H, et al: Cancer-associated fibroblast suppresses killing activity of natural killer cells through downregulation of poliovirus receptor (PVR/CD155), a ligand of activating NK receptor. Int J Oncol. 49:1297–1304. 2016. View Article : Google Scholar : PubMed/NCBI

Kerr J, Anderson C and Lippman SM: Physical activity, sedentary behaviour, diet, and cancer: An update and emerging new evidence. Lancet Oncol. 18:e457–e471. 2017. View Article : Google Scholar : PubMed/NCBI

Ni L and Dong C: New checkpoints in cancer immunotherapy. Immunol Rev. 276:52–65. 2017. View Article : Google Scholar : PubMed/NCBI

Ishida Y, Agata Y, Shibahara K and Honjo T: Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895. 1992. View Article : Google Scholar : PubMed/NCBI

Curran CS, Gupta S, Sanz I and Sharon E: PD-1 immunobiology in systemic lupus erythematosus. J Autoimmun. 97:1–9. 2019. View Article : Google Scholar : PubMed/NCBI

Jin H-T, Ahmed R and Okazaki T: Role of PD-1 in regulating T-cell immunity. 350:17–37. 2010.

Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S and Amant F: Mapping the immunosuppressive environment in uterine tumors: Implications for immunotherapy. Cancer Immunol Immunother. 63:545–557. 2014. View Article : Google Scholar : PubMed/NCBI

Mo Z, Liu J, Zhang Q, Chen Z, Mei J, Liu L, Yang S, Li H, Zhou L and You Z: Expression of PD-1, PD-L1 and PD-L2 is associated with differentiation status and histological type of endometrial cancer. Oncol Lett. 12:944–950. 2016. View Article : Google Scholar : PubMed/NCBI

Kim J, Kim S, Lee HS, Yang W, Cho H, Chay DB, Cho SJ, Hong S and Kim JH: Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. Gynecol Oncol. 149:381–387. 2018. View Article : Google Scholar : PubMed/NCBI

Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP and Zang X: The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7×, and B7-H3. Immunol Rev. 276:26–39. 2017. View Article : Google Scholar : PubMed/NCBI

Brunner A, Hinterholzer S, Riss P, Heinze G and Brustmann H: Immunoexpression of B7-H3 in endometrial cancer: Relation to tumor T-cell infiltration and prognosis. Gynecol Oncol. 124:105–111. 2012. View Article : Google Scholar : PubMed/NCBI

Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A and Shroyer KR: B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol. 106:119–127. 2007. View Article : Google Scholar : PubMed/NCBI

Bregar A, Deshpande A, Grange C, Zi T, Stall J, Hirsch H, Reeves J, Sathyanarayanan S, Growdon WB and Rueda BR: Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors. Gynecol Oncol. 145:446–452. 2017. View Article : Google Scholar : PubMed/NCBI

Ricciuti B, Leonardi GC, Puccetti P, Fallarino F, Bianconi V, Sahebkar A, Baglivo S, Chiari R and Pirro M: Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence. Pharmacol Ther. 196:105–116. 2019. View Article : Google Scholar : PubMed/NCBI

Ino K, Yoshida N, Kajiyama H, Shibata K, Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S, et al: Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer. 95:1555–1561. 2006. View Article : Google Scholar : PubMed/NCBI

de Jong RA, Kema IP, Boerma A, Boezen HM, van der Want JJ, Gooden MJ, Hollema H and Nijman HW: Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. Gynecol Oncol. 126:474–480. 2012. View Article : Google Scholar : PubMed/NCBI

Ino K, Yamamoto E, Shibata K, Kajiyama H, Yoshida N, Terauchi M, Nawa A, Nagasaka T, Takikawa O and Kikkawa F: Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: Its association with disease progression and survival. Clin Cancer Res. 14:2310–2317. 2008. View Article : Google Scholar : PubMed/NCBI

Mills A, Zadeh S, Sloan E, Chinn Z, Modesitt SC and Ring KL: Indoleamine 2,3-dioxygenase in endometrial cancer: A targetable mechanism of immune resistance in mismatch repair-deficient and intact endometrial carcinomas. Mod Pathol. 31:1282–1290. 2018. View Article : Google Scholar : PubMed/NCBI

Calviño-Sampedro C, Gomez-Tourino I, Cordero OJ, Reche PA, Gómez-Perosanz M, Sánchez-Trincado JL, Rodríguez MÁ, Sueiro AM, Viñuela JE and Calviño RV: Naturally presented HLA class I-restricted epitopes from the neurotrophic factor S100-β are targets of the autoimmune response in type 1 diabetes. FASEB J. 33:6390–6401. 2019. View Article : Google Scholar : PubMed/NCBI

Liepe J, Marino F, Sidney J, Jeko A, Bunting DE, Sette A, Kloetzel PM, Stumpf MP, Heck AJ and Mishto M: A large fraction of HLA class I ligands are proteasome-generated spliced peptides. Science. 354:354–358. 2016. View Article : Google Scholar : PubMed/NCBI

Chowell D, Morris LGT, Grigg CM, Weber JK, Samstein RM, Makarov V, Kuo F, Kendall SM, Requena D, Riaz N, et al: Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 359:582–587. 2018. View Article : Google Scholar : PubMed/NCBI

de Jong RA, Boerma A, Boezen HM, Mourits MJE, Hollema H and Nijman HW: Loss of HLA class I and mismatch repair protein expression in sporadic endometrioid endometrial carcinomas. Int J Cancer. 131:1828–1836. 2012. View Article : Google Scholar : PubMed/NCBI

Barrier BF, Kendall BS, Sharpe-Timms KL and Kost ER: Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol. 103:25–30. 2006. View Article : Google Scholar : PubMed/NCBI

Bijen CB, Bantema-Joppe EJ, de Jong RA, Leffers N, Mourits MJ, Eggink HF, van der Zee AG, Hollema H, de Bock GH and Nijman HW: The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer. Int J Cancer. 126:1417–1427. 2010.PubMed/NCBI

Lin A and Yan WH: Heterogeneity of HLA-G expression in cancers: Facing the challenges. Front Immunol. 9:21642018. View Article : Google Scholar : PubMed/NCBI

Ben Yahia H, Babay W, Bortolotti D, Boujelbene N, Laaribi AB, Zidi N, Kehila M, Chelbi H, Boudabous A, Mrad K, et al: Increased plasmatic soluble HLA-G levels in endometrial cancer. Mol Immunol. 99:82–86. 2018. View Article : Google Scholar : PubMed/NCBI

Sonoda K, Miyamoto S, Hirakawa T, Yagi H, Yotsumoto F, Nakashima M, Watanabe T and Nakano H: Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer. Gynecol Oncol. 97:772–779. 2005. View Article : Google Scholar : PubMed/NCBI

Nakashima M, Sonoda K and Watanabe T: Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1. Nat Med. 5:938–942. 1999. View Article : Google Scholar : PubMed/NCBI

Giaginis C, Giagini A and Theocharis S: Receptor-binding cancer antigen expressed on SiSo cells (RCAS1): A novel biomarker in the diagnosis and prognosis of human neoplasia. Histol Histopathol. 24:761–776. 2009.PubMed/NCBI

Sonoda K, Kaku T, Hirakawa T, Kobayashi H, Amada S, Sakai K, Nakashima M, Watanabe T and Nakano H: The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. Gynecol Oncol. 79:424–429. 2000. View Article : Google Scholar : PubMed/NCBI

Sonoda K, Miyamoto S, Hirakawa T, Kaku T, Nakashima M, Watanabe T, Akazawa K, Fujita T and Nakano H: Association between RCAS1 expression and clinical outcome in uterine endometrial cancer. Br J Cancer. 89:546–551. 2003. View Article : Google Scholar : PubMed/NCBI

Szubert S, Koper K, Dutsch-Wicherek MM and Kojs Z: The potential predictive value of serum srCaS1 levels for overall survival in endometrial cancer. Ginekol Pol. 90:134–140. 2019. View Article : Google Scholar : PubMed/NCBI

Rand AA, Barnych B, Morisseau C, Cajka T, Lee KS, Panigrahy D and Hammock BD: Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids. Proc Natl Acad Sci USA. 114:4370–4375. 2017. View Article : Google Scholar : PubMed/NCBI

Elling R, Robinson EK, Shapleigh B, Liapis SC, Covarrubias S, Katzman S, Groff AF, Jiang Z, Agarwal S, Motwani M, et al: Genetic models reveal cis and trans immune-regulatory activities for lincRNA-Cox2. Cell Reports. 25:1511–1524.e1516. 2018. View Article : Google Scholar : PubMed/NCBI

Tang H, Liu Y, Wang C, Zheng H, Chen Y, Liu W, Chen X, Zhang J, Chen H, Yang Y, et al: Inhibition of COX-2 and EGFR by melafolone improves anti-PD-1 therapy through vascular normalization and PD-L1 downregulation in lung cancer. J Pharmacol Exp Ther. 368:401–413. 2019. View Article : Google Scholar : PubMed/NCBI

Ohno Y, Ohno S, Suzuki N, Kamei T, Inagawa H, Soma G and Inoue M: Role of cyclooxygenase-2 in immunomodulation and prognosis of endometrial carcinoma. Int J Cancer. 114:696–701. 2005. View Article : Google Scholar : PubMed/NCBI

Suemori T, Susumu N, Iwata T, Banno K, Yamagami W, Hirasawa A, Sugano K, Matsumoto E and Aoki D: Intratumoral CD8⁺ lymphocyte infiltration as a prognostic factor and its relationship with cyclooxygenase 2 expression and microsatellite instability in endometrial cancer. Int J Gynecol Cancer. 25:1165–1172. 2015. View Article : Google Scholar : PubMed/NCBI

Ols ML, Cullen JL, Turqueti-Neves A, Giles J and Shlomchik MJ: Dendritic cells regulate extrafollicular autoreactive B cells via T cells expressing Fas and Fas ligand. Immunity. 45:1052–1065. 2016. View Article : Google Scholar : PubMed/NCBI

Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K and Nishimura R: Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer. 82:1682–1688. 2000.PubMed/NCBI

Jia JJ, Wang ZN, Liu GX and Wang ZX: Apoptosis and expression of Fas/FasL in tumor infiltrating dendritic cells in human endometrioid adenocarcinoma. Nan Fang Yi Ke Da Xue Xue Bao. 31:1693–1696. 2011.(In Chinese). PubMed/NCBI

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Fang HB, Cai L, Janofsky S, Chew A, Storek J, Akpek G, et al: Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood. 117:788–797. 2011. View Article : Google Scholar : PubMed/NCBI

Végran F, Mary R, Gibeaud A, Mirjolet C, Collin B, Oudot A, Charon-Barra C, Arnould L, Lizard-Nacol S and Boidot R: Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy. Cancer Res. 73:5391–5401. 2013. View Article : Google Scholar : PubMed/NCBI

Wang Z, Liu Y and Liu M: Platelet-rich plasma injection is not more effective than hyaluronic acid to treat knee osteoarthritis when using a random-effects model. Br J Sports Med. 50:953–954. 2016. View Article : Google Scholar : PubMed/NCBI

Chuwa AH, Sone K, Oda K, Ikeda Y, Fukuda T, Wada-Hiraike O, Inaba K, Makii C, Takeuchi M, Oki S, et al: Significance of survivin as a prognostic factor and a therapeutic target in endometrial cancer. Gynecol Oncol. 141:564–569. 2016. View Article : Google Scholar : PubMed/NCBI

Kumar A, Sirohi VK, Anum F, Singh PK, Gupta K, Gupta D, Saraf SA, Dwivedi A and Chourasia MK: Enhanced apoptosis, survivin down-regulation and assisted immunochemotherapy by curcumin loaded amphiphilic mixed micelles for subjugating endometrial cancer. Nanomedicine (Lond). 13:1953–1963. 2017. View Article : Google Scholar

Kang S, Tanaka T, Narazaki M and Kishimoto T: Targeting Interleukin-6 Signaling in Clinic. Immunity. 50:1007–1023. 2019. View Article : Google Scholar : PubMed/NCBI

Bellone S, Watts K, Cane' S, Palmieri M, Cannon MJ, Burnett A, Roman JJ, Pecorelli S and Santin AD: High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol. 98:92–98. 2005. View Article : Google Scholar : PubMed/NCBI

Ren Y, Zhang Y, Liu RZ, Fenstermacher DA, Wright KL, Teer JK and Wu J: JAK1 truncating mutations in gynecologic cancer define new role of cancer-associated protein tyrosine kinase aberrations. Sci Rep. 3:30422013. View Article : Google Scholar : PubMed/NCBI

Albacker LA, Wu J, Smith P, Warmuth M, Stephens PJ, Zhu P, Yu L and Chmielecki J: Loss of function JAK1 mutations occur at high frequency in cancers with microsatellite instability and are suggestive of immune evasion. PLoS One. 12:e01761812017. View Article : Google Scholar : PubMed/NCBI

Chao A, Tang YH, Lai CH, Chang CJ, Chang SC, Wu TI, Hsueh S, Wang CJ, Chou HH and Chang TC: Potential of an age-stratified CA125 cut-off value to improve the prognostic classification of patients with endometrial cancer. Gynecol Oncol. 129:500–504. 2013. View Article : Google Scholar : PubMed/NCBI

Hu J and Sun J: MUC16 mutations improve patients' prognosis by enhancing the infiltration and antitumor immunity of cytotoxic T lymphocytes in the endometrial cancer microenvironment. OncoImmunology. 7:e14879142018. View Article : Google Scholar : PubMed/NCBI

Grotzke JE, Sengupta D, Lu Q and Cresswell P: The ongoing saga of the mechanism(s) of MHC class I-restricted cross-presentation. Curr Opin Immunol. 46:89–96. 2017. View Article : Google Scholar : PubMed/NCBI

Chen Y, Li H, Xiao C, Zeng X, Xiao X, Zhou Q and Xiao P: NLRC5: Potential novel non-invasive biomarker for predicting and reflecting the progression of IgA nephritis. J Transl Med. 16:3172018. View Article : Google Scholar : PubMed/NCBI

Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, Sidiq T, Shipp MA, Lizee GA and Kobayashi KS: NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci USA. 113:5999–6004. 2016. View Article : Google Scholar : PubMed/NCBI

Mao Y, Poschke I, Wennerberg E, Pico de Coaña Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G, Lundqvist A and Kiessling R: Melanoma-educated CD14⁺ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res. 73:3877–3887. 2013. View Article : Google Scholar : PubMed/NCBI

Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK and Dubinett SM: Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4⁺ CD25⁺ T regulatory cell activities in lung cancer. Cancer Res. 65:5211–5220. 2005. View Article : Google Scholar : PubMed/NCBI

St-Germain ME, Gagnon V, Parent S and Asselin E: Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-kappaB/IkappaB pathway. Mol Cancer. 3:72004. View Article : Google Scholar : PubMed/NCBI

Mulati K, Hamanishi J, Matsumura N, Chamoto K, Mise N, Abiko K, Baba T, Yamaguchi K, Horikawa N, Murakami R, et al: VISTA expressed in tumour cells regulates T cell function. Br J Cancer. 120:115–127. 2019. View Article : Google Scholar : PubMed/NCBI

Zsiros E and Odunsi K: Tumor-associated macrophages: Co-conspirators and orchestrators of immune suppression in endometrial adenocarcinoma. Gynecol Oncol. 135:173–175. 2014. View Article : Google Scholar : PubMed/NCBI

Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A and Locati M: The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25:677–686. 2004. View Article : Google Scholar : PubMed/NCBI

Yoshida N, Ino K, Ishida Y, Kajiyama H, Yamamoto E, Shibata K, Terauchi M, Nawa A, Akimoto H, Takikawa O, et al: Overexpression of indoleamine 2,3-dioxygenase in human endometrial carcinoma cells induces rapid tumor growth in a mouse xenograft model. Clin Cancer Res. 14:7251–7259. 2008. View Article : Google Scholar : PubMed/NCBI

Check JH and Cohen R: The role of progesterone and the progesterone receptor in human reproduction and cancer. Expert Rev Endocrinol Metab. 8:469–484. 2013. View Article : Google Scholar : PubMed/NCBI

Yang L, Huang F, Mei J, Wang X, Zhang Q, Wang H, Xi M and You Z: Posttranscriptional control of PD-L1 expression by 17β-estradiol via PI3K/Akt signaling pathway in ERα-positive cancer cell lines. Int J Gynecol Cancer. 27:196–205. 2017. View Article : Google Scholar : PubMed/NCBI

Ning C, Xie B, Zhang L, Li C, Shan W, Yang B, Luo X, Gu C, He Q, Jin H, et al: Infiltrating macrophages induce ERα expression through an IL17A-mediated epigenetic mechanism to sensitize endometrial cancer cells to estrogen. Cancer Res. 76:1354–1366. 2016. View Article : Google Scholar : PubMed/NCBI

Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, Lamb T, Mani A, Kane Y, Balint CR, et al: Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol. 27:5270–5277. 2009. View Article : Google Scholar : PubMed/NCBI

Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimura T, et al: Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res. 29:4779–4784. 2009.PubMed/NCBI

Jäger E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jäger D, et al: Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA. 103:14453–14458. 2006. View Article : Google Scholar : PubMed/NCBI

Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D'Andrea AD, Wu CJ, et al: Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 1:1319–1323. 2015. View Article : Google Scholar : PubMed/NCBI

Mehnert JM, Panda A, Zhong H, Hirshfield K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L, Kaufman HL, et al: Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer. J Clin Invest. 126:2334–2340. 2016. View Article : Google Scholar : PubMed/NCBI

Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, et al: Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: Results from the KEYNOTE-028 study. J Clin Oncol. 35:2535–2541. 2017. View Article : Google Scholar : PubMed/NCBI

Osterman C, McCarthy MBR, Cote MP, Beitzel K, Bradley J, Polkowski G and Mazzocca AD: Platelet-rich plasma increases anti-inflammatory markers in a human coculture model for osteoarthritis. Am J Sports Med. 43:1474–1484. 2015. View Article : Google Scholar : PubMed/NCBI

Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, et al: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: An interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20:711–718. 2019. View Article : Google Scholar : PubMed/NCBI

Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al: Cancer immunotherapy based on mutation-specific CD4⁺ T cells in a patient with epithelial cancer. Science. 344:641–645. 2014. View Article : Google Scholar : PubMed/NCBI

de Bono JS, Concin N, Hong DS, Thistlethwaite FC, Machiels JP, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, et al: Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): A first-in-human, multicentre, phase 1–2 trial. Lancet Oncol. 20:383–393. 2019. View Article : Google Scholar : PubMed/NCBI

Tuyaerts S, Van Nuffel AMT, Naert E, Van Dam PA, Vuylsteke P, De Caluwé A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, et al: PRIMMO study protocol: A phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. BMC Cancer. 19:5062019. View Article : Google Scholar : PubMed/NCBI

Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm GB, Yuan Y, Mok SC, Broaddus RR, Lu KH and Yates MS: Immune microenvironment in microsatellite-instable endometrial cancers: Hereditary or sporadic origin matters. Clin Cancer Res. 23:4473–4481. 2017. View Article : Google Scholar : PubMed/NCBI

Temko D, Van Gool IC, Rayner E, Glaire M, Makino S, Brown M, Chegwidden L, Palles C, Depreeuw J, Beggs A, et al: Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. J Pathol. 245:283–296. 2018. View Article : Google Scholar : PubMed/NCBI

Eggink FA, Van Gool IC, Leary A, Pollock PM, Crosbie EJ, Mileshkin L, Jordanova ES, Adam J, Freeman-Mills L, Church DN, et al: Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. OncoImmunology. 6:e12645652016. View Article : Google Scholar : PubMed/NCBI

Talhouk A, Derocher H, Schmidt P, Leung S, Milne K, Gilks CB, Anglesio MS, Nelson BH and McAlpine JN: Molecular subtype not immune response drives outcomes in endometrial carcinoma. Clin Cancer Res. 25:2537–2548. 2019. View Article : Google Scholar : PubMed/NCBI

Mullen MM and Mutch DG: Endometrial tumor immune response: Predictive biomarker of response to immunotherapy. Clin Cancer Res. 25:2366–2368. 2019. View Article : Google Scholar : PubMed/NCBI

DeLong P, Tanaka T, Kruklitis R, Henry AC, Kapoor V, Kaiser LR, Sterman DH and Albelda SM: Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy. Cancer Res. 63:7845–7852. 2003.PubMed/NCBI

Han Y, Qin W and Huang G: Knockdown of RCAS1 expression by RNA interference recovers T cell growth and proliferation. Cancer Lett. 257:182–190. 2007. View Article : Google Scholar : PubMed/NCBI

Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M, Todeschini P, Krikun G, Silasi DA, Azodi M, et al: hI-con1, a factor VII–IgGFc chimeric protein targeting tissue factor for immunotherapy of uterine serous papillary carcinoma. Br J Cancer. 103:812–819. 2010. View Article : Google Scholar : PubMed/NCBI

Varughese J, Cocco E, Bellone S, de Leon M, Bellone M, Todeschini P, Schwartz PE, Rutherford TJ, Pecorelli S and Santin AD: Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer. 117:3163–3172. 2011. View Article : Google Scholar : PubMed/NCBI

Vanderstraeten A, Everaert T, Van Bree R, Verbist G, Luyten C, Amant F and Tuyaerts S: In vitro validation of survivin as target tumor-associated antigen for immunotherapy in uterine cancer. J Immunother. 38:239–249. 2015. View Article : Google Scholar : PubMed/NCBI

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, et al: A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer. Ann Oncol. 26:2141–2149. 2015. View Article : Google Scholar : PubMed/NCBI

Rader JS, Aylsworth CF, Juckett DA, Mutch DG, Powell MA, Lippmann L and Dimitrov NV: Phase I study and preliminary pharmacology of the novel innate immune modulator rBBX-01 in gynecologic cancers. Clin Cancer Res. 14:3089–3097. 2008. View Article : Google Scholar : PubMed/NCBI